Insperity reported earnings on July 29 and the stock's subsequent move has forced a rapid rethink from the shorts who spent the past month building defensive positioning ahead of that print.
The reversal in short interest is the clearest story in the data this week. SI has dropped 11.6% in seven days to 10.0% of the free float — down from 11.3% when the previous note flagged heavy put buying ahead of the report. That's a meaningful covering run, with the sharpest single-day drop coming on July 23, when shares outstanding short fell by roughly half a million in one session. The stock is up 26.9% over the past month, now trading at $52.58, and that kind of move compresses the thesis for bears quickly. The borrow market corroborates: cost to borrow has eased 7% on the week to just 0.51%, and availability is running at 484% — more than four shares available to borrow for every one already lent out. There is no squeeze pressure, no tightening pool. Shorts who remain are staying in at minimal cost, and those who covered did so without any friction.
Options positioning has also unwound from the extreme reached last week. The previous note flagged a put/call ratio near the 52-week high at 2.71, with a z-score close to 3.0 — a genuinely unusual reading. The PCR has eased to 2.42, still well above its 20-day mean of 1.84, and the z-score has fallen back to around 1.0. The options market is no longer flashing a red alert. It remains more defensive than average — puts still outnumber calls by more than two-to-one — but the panic hedge that was in place heading into the print has partially unwound. That pivot in options, combined with the short covering, tells a consistent story: the trade that was braced for a repeat of the April disaster did not pay off.
The Street remains cautious, even as the price has run well past most targets. Truist Securities raised its target to $52 on July 22 — literally the current price — maintaining a Hold. JPMorgan holds at Underweight with a $33 target, roughly 37% below the market. The consensus mean target is $43.75, meaning the stock is now trading at an 18% premium to the average analyst view. That gap is notable. Bulls point to Insperity's Workday partnership, PEO industry tailwinds, and a 4% revenue growth path toward $1.62 billion. Bears flag persistent healthcare cost pressure and sluggish new hiring among WSEEs. The factor scores offer little comfort to either side: the short score sits at 57.3, down from 60.6 earlier in the week as covering pressure eased, and the EPS surprise rank at 40 is below the median — the company has not been a consistent beat story. The PE multiple has expanded to 21.2x, up 3.6 points over the past 30 days, driven entirely by price appreciation rather than earnings revision.
The insider ownership angle remains a structural backdrop worth keeping in mind. CEO Paul Sarvadi spent roughly $15.7 million buying shares between March and June, accumulating at prices ranging from $22 to $34. He now holds 4.57% of the company. That buying cluster, which looked aggressive at the time and now looks well-timed, is the clearest source of fundamental conviction in the data — and it came from inside the building. Reinhart Partners added 356,000 shares in the most recent quarter, the largest active-manager move in the top-holders table.
The April earnings print saw NSP fall 23.3% in a single session and lose a further 12.1% over the following five days. The July print appears to have broken that pattern — the stock is up on the week rather than down. What to watch next is whether the analyst community upgrades through the current price, or whether the gap between consensus targets and the market price widens further and begins to weigh on momentum.
See the live data behind this article on ORTEX.
Open NSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
